These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

184 related articles for article (PubMed ID: 34667923)

  • 21. Efficacy of rFIXFc versus N9-GP Prophylaxis in Patients with Hemophilia B: Matching-Adjusted Indirect Comparison of B-LONG and PARADIGM 2 Trials.
    Mancuso ME; Eriksson D; Falk A; Hakimi Z; Wojciechowski P; Wdowiak M; Klamroth R
    J Blood Med; 2023; 14():427-434. PubMed ID: 37534261
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Long-acting recombinant factor IX Fc fusion protein (rFIXFc) for perioperative management of subjects with haemophilia B in the phase 3 B-LONG study.
    Powell JS; Apte S; Chambost H; Hermans C; Jackson S; Josephson NC; Mahlangu JN; Ozelo MC; Peerlinck K; Pasi J; Perry D; Ragni MV; Wang X; Jiang H; Li S; Cristiano LM; Innes A; Nugent K; Brennan A; Luk A; Allen G; Pierce GF; Robinson B
    Br J Haematol; 2015 Jan; 168(1):124-34. PubMed ID: 25208598
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Recombinant factor IX-Fc fusion protein (rFIXFc) demonstrates safety and prolonged activity in a phase 1/2a study in hemophilia B patients.
    Shapiro AD; Ragni MV; Valentino LA; Key NS; Josephson NC; Powell JS; Cheng G; Thompson AR; Goyal J; Tubridy KL; Peters RT; Dumont JA; Euwart D; Li L; Hallén B; Gozzi P; Bitonti AJ; Jiang H; Luk A; Pierce GF
    Blood; 2012 Jan; 119(3):666-72. PubMed ID: 22110246
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Final results of the PUPs B-LONG study: evaluating safety and efficacy of rFIXFc in previously untreated patients with hemophilia B.
    Nolan B; Klukowska A; Shapiro A; Rauch A; Recht M; Ragni M; Curtin J; Gunawardena S; Mukhopadhyay S; Jayawardene D; Winding B; Fischer K; Liesner R
    Blood Adv; 2021 Jul; 5(13):2732-2739. PubMed ID: 34242387
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Extending recombinant factor IX Fc fusion protein dosing interval to 14 or more days in patients with hemophilia B.
    Shapiro AD; Pasi KJ; Ozelo MC; Kulkarni R; Barnowski C; Winding B; Szamosi J; Lethagen S
    Res Pract Thromb Haemost; 2019 Jan; 3(1):109-113. PubMed ID: 30656283
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Cost-effectiveness analysis of recombinant factor IX Fc fusion protein compared with recombinant factor IX for the treatment of moderate-severe to severe hemophilia B in China.
    Zhou T; Wang S; Zhang Y; Wu R; Li H
    Pediatr Blood Cancer; 2023 Jun; 70(6):e30264. PubMed ID: 36815588
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Eftrenonacog Alfa: A Review in Haemophilia B.
    Hoy SM
    Drugs; 2017 Jul; 77(11):1235-1246. PubMed ID: 28646426
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Surgical outcomes in patients with haemophilia A or B receiving extended half-life recombinant factor VIII and IX Fc fusion proteins: Real-world experience in the Nordic countries.
    Lehtinen AE; Baghaei F; Astermark J; Holme PA
    Haemophilia; 2022 Sep; 28(5):713-719. PubMed ID: 35575446
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Population pharmacokinetic modelling of recombinant factor IX Fc fusion protein (rFIXFc) in patients with haemophilia B.
    Diao L; Li S; Ludden T; Gobburu J; Nestorov I; Jiang H
    Clin Pharmacokinet; 2014 May; 53(5):467-77. PubMed ID: 24452809
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Eftrenonacog Alfa: A Review in Haemophilia B.
    Lamb YN; Hoy SM
    Drugs; 2023 Jun; 83(9):807-818. PubMed ID: 37081241
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Physical activity and bleeding outcomes among people with severe hemophilia on extended half-life or conventional recombinant factors.
    Shrestha A; Su J; Li N; Barnowski C; Jain N; Everson K; Jena AB; Batt K
    Res Pract Thromb Haemost; 2021 Jan; 5(1):94-103. PubMed ID: 33537533
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Post hoc longitudinal assessment of the efficacy and safety of recombinant factor IX Fc fusion protein in hemophilia B.
    Shapiro AD; Kulkarni R; Ragni MV; Chambost H; Mahlangu J; Oldenburg J; Nolan B; Ozelo MC; Foster MC; Willemze A; Barnowski C; Jain N; Winding B; Dumont J; Lethagen S; Barnes C; Pasi KJ
    Blood Adv; 2023 Jul; 7(13):3049-3057. PubMed ID: 36848635
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Changes in health-related quality of life with treatment of longer-acting clotting factors: results in the A-LONG and B-LONG clinical studies.
    Wyrwich KW; Krishnan S; Auguste P; Poon JL; von Maltzahn R; Yu R; Pierce GF; Mei B; Mahlangu J; von Mackensen S
    Haemophilia; 2016 Nov; 22(6):866-872. PubMed ID: 27385432
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Evaluation of the toxicology, pharmacokinetics, and local tolerance of recombinant factor IX Fc fusion protein in animals.
    Dumont JA; Loveday KS; Light DR; Pierce GF; Jiang H
    Thromb Res; 2015 Aug; 136(2):371-8. PubMed ID: 25840744
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Biodistribution of recombinant factor IX, extended half-life recombinant factor IX Fc fusion protein, and glycoPEGylated recombinant factor IX in hemophilia B mice.
    van der Flier A; Hong V; Liu Z; Piepenhagen P; Ulinski G; Dumont JA; Orcutt KD; Goel A; Peters R; Salas J
    Blood Coagul Fibrinolysis; 2023 Sep; 34(6):353-363. PubMed ID: 37577860
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Recombinant factor IX Fc for the treatment of hemophilia B.
    Ljung R; Matino D; Shapiro AD
    Eur J Haematol; 2024 May; 112(5):678-691. PubMed ID: 38369860
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Prophylaxis with recombinant factor IX Fc fusion protein reduces the risk of bleeding and delays time to first spontaneous bleed event in previously untreated patients with haemophilia B: A post hoc analysis of the PUPs B-LONG study.
    Nolan B; Recht M; Rendo P; Falk A; Foster M; Casiano S; Rauch A; Shapiro A
    Eur J Haematol; 2024 Jun; ():. PubMed ID: 38922990
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Prolonged activity of factor IX as a monomeric Fc fusion protein.
    Peters RT; Low SC; Kamphaus GD; Dumont JA; Amari JV; Lu Q; Zarbis-Papastoitsis G; Reidy TJ; Merricks EP; Nichols TC; Bitonti AJ
    Blood; 2010 Mar; 115(10):2057-64. PubMed ID: 20056791
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Physical activity in individuals with haemophilia and experience with recombinant factor VIII Fc fusion protein and recombinant factor IX Fc fusion protein for the treatment of active patients: a literature review and case reports.
    Wang M; Álvarez-Román MT; Chowdary P; Quon DV; Schafer K
    Blood Coagul Fibrinolysis; 2016 Oct; 27(7):737-744. PubMed ID: 27116081
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Favorable pharmacokinetics in hemophilia B for nonacog beta pegol versus recombinant factor IX-Fc fusion protein: A randomized trial.
    Escuriola Ettingshausen C; Hegemann I; Simpson ML; Cuker A; Kulkarni R; Pruthi RK; Garly ML; Meldgaard RM; Persson P; Klamroth R
    Res Pract Thromb Haemost; 2019 Apr; 3(2):268-276. PubMed ID: 31011711
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.